. home.aspx



AbbVie leverages Dragonfly’s NK cell immunotherapy technology

November 21, 2019 / Allie Nawrat

US-based Dragonfly Therapeutics has announced it has signed a multi-target collaboration with AbbVie to advance immunotherapies created using its Tri-specific Natural Killer (NK) cell engager Therapies (TriNKET) technology for autoimmune and oncology indications. AbbVie has made an undisclosed upfront payment to Dragonfly, and has agreed to future success-based milestone and royalty payments. As a result of the agreement, AbbVie will have the option to license exclusive, global rights to develop and commercialise products created using Dragonfly’s TriNKET technology. AbbVie senior vice-president of R&D and chief scientific officer Tom Hudson said: “AbbVie is committed to delivering improved treatment options to our patients by investing in ground breaking technologies and platforms. “The Dragonfly team has made impressive progress in developing their platform and demonstrating the potential of their technology to potentially treat a variety of diseases.” Dra...